DFO
PTGX icon

Duquesne Family Office’s Protagonist Therapeutics PTGX Stock Holding History

Duquesne Family Office’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.8M Hold
159,700
– – 0.5% 44
2025
Q4 		$13.9M Hold
159,700
– – 0.31% 49
2025
Q3 		$10.6M Buy
+159,700
New +$9.08M 0.26% 57

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Duquesne Family Office's PTGX Position: Q1 2026 in Review

Duquesne Family Office held its Protagonist Therapeutics (PTGX) position steady in Q1 2026 at 159,700 shares worth $16.8M. The position accounts for 0.5% of the portfolio, ranked #44.

Duquesne Family Office first reported a position in PTGX in Q3 2025 and has held it in 3 quarters since. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Duquesne Family Office held 159,700 shares of Protagonist Therapeutics worth $16.8M as of Q1 2026.
  • Duquesne Family Office left its Protagonist Therapeutics share count unchanged in Q1 2026.
  • Protagonist Therapeutics made up 0.5% of Duquesne Family Office's portfolio in Q1 2026, its #44 holding.
  • Duquesne Family Office first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Duquesne Family Office's 13F filing for Q1 2026, filed 15 May 2026.